Two members of the RI-MUHC elected fellows of the Canadian Academy of Health Sciences
Congratulations to Marina Klein and Bernard Robaire!
The COVID-19 Immunity Task Force funds comprehensive new SARS-CoV-2 seroprevalence study focused on aging Canadians
RI-MUHC researcher Christina Wolfson co-leads study investing in our most...
Spike in peanut and nut anaphylaxis in children at Halloween and Easter
New study suggests education and awareness are needed to help reduce risk of anaphylaxis at specific times of the year
$2M funding to mitigate COVID-19 impact on tuberculosis services
Dr. Madhukar Pai launches studies in India, Indonesia, Nigeria and Peru
Sleep apnea treatment reduces heart problems in patients with prediabetes, a new study finds
People with prediabetes and obstructive sleep apnea could reduce their daytime resting heart rate and risk of cardiovascular disease by using a CPAP machine at night
New study of therapy options in metastatic melanoma
RI-MUHC researchers lead “real-world” analysis of treatment patterns with checkpoint inhibitors
Nip it in the bud: New study will attack SARS-Cov2 where it multiplies
RI-MUHC researchers initiate a clinical trial of ciclesonide to possibly prevent mild cases of COVID-19 from worsening
Serious Flaws in Studies Linking COVID-19 and Air Pollution
Studies have yet to prove this link, say Carleton and McGill University epidemiologists
Systematic testing of groups at increased risk of SARS-CoV-2: an affordable and reasonable approach
In a new cost-analysis study, researchers recommend widespread testing of...
Old drug, new therapy: RI-MUHC-sponsored phase III clinical trial ready to test repurposed dapsone to tone down lung inflammation caused by COVID-19
Reformulated and patented version of well-known generic drug could prove to be a quick, safe and cost-effective way to accelerate recovery and prevent hospitalizations